WallStreetZenWallStreetZen

NASDAQ: VANI
Vivani Medical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their VANI stock forecasts and price targets.

Forecast return on equity

Is VANI forecast to generate an efficient return?

Company
N/A
Industry
66.72%
Market
181.06%

Forecast return on assets

Is VANI forecast to generate an efficient return on assets?

Company
N/A
Industry
32.08%

VANI earnings per share forecast

What is VANI's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.36
Avg 2 year Forecast
-$0.49

VANI revenue forecast

What is VANI's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

VANI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VANI$1.10N/AN/A
ATHE$3.60N/AN/A
SPRB$60.06$203.25+238.41%Buy
MCRB$8.63$22.00+154.92%Strong Buy
PMVP$1.56N/AN/A
View Top Biotech Stocks

Vivani Medical Stock Forecast FAQ

What is VANI's earnings growth forecast for 2026-2027?

(NASDAQ: VANI) Vivani Medical's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.

Vivani Medical's earnings in 2026 is -$26,026,000.On average, 4 Wall Street analysts forecast VANI's earnings for 2026 to be -$26,043,948, with the lowest VANI earnings forecast at -$25,022,617, and the highest VANI earnings forecast at -$26,809,946.

In 2027, VANI is forecast to generate -$35,717,414 in earnings, with the lowest earnings forecast at -$34,316,731 and the highest earnings forecast at -$36,767,926.

If you're new to stock investing, here's how to buy Vivani Medical stock.

What is VANI's revenue growth forecast for 2026-2028?

(NASDAQ: VANI) Vivani Medical's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.

Vivani Medical's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast VANI's revenue for 2026 to be $0, with the lowest VANI revenue forecast at $0, and the highest VANI revenue forecast at $0. On average, 3 Wall Street analysts forecast VANI's revenue for 2027 to be $0, with the lowest VANI revenue forecast at $0, and the highest VANI revenue forecast at $0.

In 2028, VANI is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is VANI's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VANI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 32.08%.

What is VANI's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: VANI) Vivani Medical's current Earnings Per Share (EPS) is -$0.45. On average, analysts forecast that VANI's EPS will be -$0.36 for 2026, with the lowest EPS forecast at -$0.34, and the highest EPS forecast at -$0.37. In 2027, VANI's EPS is forecast to hit -$0.49 (min: -$0.47, max: -$0.50).

What is VANI's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VANI) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.